G2082 applies to a supervised esketamine dose of 56 mg or less; G2083 applies above 56 mg. Both include the visit, esketamine provision, and two-hour observation.
On this page
CMS RVU26D · Effective 2026-10-01
G2083 Esketamine visit Medicare reimbursement rates in Massachusetts
Reports an established-patient office or outpatient visit for supervised esketamine treatment when the administered dose exceeds 56 mg, including observation. Compare G2083 office and facility rates across CMS payment localities in Massachusetts.
Amounts below use the non-QP conversion factor for participating physicians. These are base physician payments before claim-level adjustments, not patient costs or total hospital charges.
What does Medicare pay for G2083 in Massachusetts?
Massachusetts has 2 payment localities in this comparison. Use the service location to choose the applicable amount. These are the supported base rates for the 2 payment areas shown below, using the same CMS release.
Office / nonfacility
$1426.48–$1614.87
2 of 2 localities have a supported rate.
Facility setting
$31.25–$32.80
2 of 2 localities have a supported rate.
These are locality ranges, not averages or address-specific quotes. A facility-setting amount covers the physician service; it does not include a hospital’s separate bill. Choose a locality below to inspect its calculation, compare other payment areas, or price a percentage of Medicare.
Behavioral health
About G2083: Established patient esketamine visit over 56 mg
Reports an established-patient office or outpatient visit for supervised esketamine treatment when the administered dose exceeds 56 mg, including observation.
G2083 covers an established-patient office or outpatient encounter for esketamine treatment when the dose exceeds 56 mg. A physician or other qualified health care professional supervises the treatment, during which the patient self-administers intranasal esketamine under clinical supervision. This service is commonly provided in a clinic treating adults with treatment-resistant depression. The code includes the esketamine and two hours of post-administration observation.
Choose G2083 based on the total dose administered: it is for doses above 56 mg, while G2082 is for 56 mg or less. The record should support established-patient status, the clinical evaluation, the administered dose, supervision, and the observation. The visit, esketamine provision, and two-hour observation are packaged in the code; do not separately report those same services as though they were independent services.
Where the value comes from
- Work RVU0.70 · 2%
- Practice expense (office) RVU39.83 · 98%
- Malpractice RVU0.07 · 0%
33.7K
Medicare services in 2024 · #934 by national volume
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
G2083 compared with similar codes
Office rates for Massachusetts, from the same CMS release.
99213 reports an established-patient E/M service without the bundled esketamine treatment. G2083 includes E/M as part of the supervised treatment visit.
99214 reports an established-patient E/M service without the bundled esketamine treatment. Use G2083 for the qualifying supervised esketamine visit rather than separately reporting its included E/M work.
Compare G2083 by payment locality
Find the payment area for your service address, then open its rate page for calculation inputs, release history and the percentage-of-Medicare tool. A city may cross payment-area boundaries; the ZIP lookup above helps resolve the location.
2 of 2 payment localities
Metropolitan Boston →
Office / nonfacility
$1614.87
Facility
$32.80
Rest Of Massachusetts →
Office / nonfacility
$1426.48
Facility
$31.25
Need rates for a whole code list?
Fee-sheet and API access are in early access. Tell us which codes and locations your team needs.
G2083 billing questions
When should the clinic use G2083 instead of G2082?
Use G2083 when the esketamine dose administered is more than 56 mg. Use G2082 for a dose of 56 mg or less.
Does G2083 include the esketamine and observation?
Yes. The service includes provision of esketamine and two hours of post-administration observation.
Can the clinic bill a separate E/M code for the same visit?
The E/M service is included in G2083. Do not separately report the same evaluation and management work.
Is the code selected based on observation time?
No. The distinguishing threshold is the administered esketamine dose, not a longer observation period.
What dose documentation supports G2083?
Document the total esketamine dose administered, along with the evaluation, supervision, and post-administration observation.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense, and malpractice RVUs, adjusted by each locality’s geographic indices and the applicable conversion factor. Unavailable or separately priced services are labeled rather than assigned a made-up amount.
Source: RVU26D. Effective 2026-10-01 through the day before 2027-01-01.
